Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,293 shares of the company's common stock for $7,752 to cover tax withholding obligations from Restricted Stock Unit vesting. Despite the sale, Shah retains a significant stake in the company. Rocket Pharmaceuticals recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, while analysts maintain a "Hold" rating on its stock.
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com
Rocket Pharmaceuticals General Counsel Martin Wilson sold 631 shares worth $2,133 to cover tax obligations from RSU vesting, retaining 673,853 shares. The company recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and held its annual meeting, electing new directors. TD Cowen maintained a Hold rating, noting positive safety observations for its RP-A501 gene therapy program.
Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill
Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a vested equity award distribution. Shah has made several other sales of RCKT common stock in the past three months, including 2,409 shares on May 19, 2026, 55,684 shares on May 21, 2026, and 2,837 shares on August 13, 2026.
Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares
A former officer of Rocket Pharmaceuticals (NASDAQ: RCKT), John Militello, has filed a Form 144 notice to sell 1,252 shares of common stock. The filing, dated August 18, 2026, details two recent restricted stock vesting events in August 2026 and a sale of 384 shares in May 2026, part of which was to cover tax obligations from an equity award distribution. The total market value of the shares to be sold is stated as $4,233.51.
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,837 shares of company stock worth $9,591 to cover tax obligations from vested Restricted Stock Units. Despite this sale, Shah retains significant holdings. The company also recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million and approved new directors, indicating ongoing strategic activities.
RCKT Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Rocket Pharmaceuticals (RCKT), including its recent sale of a Rare Pediatric Disease Priority Review Voucher for $180 million, significantly increasing its cash reserves. It also details a positive clinical safety update for its RP-A501 gene therapy in Danon disease and lists recent FDA approvals and conference attendances.
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock
Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson sold 3,493 shares of the company's stock, valued at $11,806.34, to cover tax withholding obligations tied to vested equity awards. This transaction reduced his holdings by 0.52%. Despite the insider sale, Rocket Pharmaceuticals recently reported quarterly earnings per share of $1.08, surpassing analyst estimates, and maintains an average "Hold" rating with a consensus price target of $8.57 from analysts.
Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT
Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating quarterly EPS expectations, analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $8.57. Rocket Pharmaceuticals, which develops gene therapies for rare pediatric diseases, continues to trade near the lower end of its 52-week range.
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the past 90 days. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing gene therapies for rare, inherited pediatric diseases and recently reported an EPS of $1.08, exceeding estimates.
Don't Ignore The Insider Selling In Rocket Pharmaceuticals
The Chief Operating Officer at Rocket Pharmaceuticals, Christopher Stevens, recently sold US$128k worth of shares, which constituted 6.8% of his holdings. While the sale occurred at the current stock price, suggesting it's not a major concern, the article highlights a trend of more insider selling than buying over the past year. Despite some insider ownership, the overall picture suggests caution is warranted for potential investors.
Don't Ignore The Insider Selling In Rocket Pharmaceuticals
A Chief Operating Officer at Rocket Pharmaceuticals recently sold US$128k worth of shares, representing 6.8% of their holding. This sale was the largest insider sale in the past year, though it occurred around the current market price, making it less concerning than sales at lower prices. The overall trend for Rocket Pharmaceuticals shows more insider selling than buying over the last year, suggesting caution despite insiders owning 3.6% of the company.
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock
Sarbani Chaudhuri, an insider at Rocket Pharmaceuticals (NASDAQ:RCKT), sold 4,701 shares of the company's stock for $16,453.50 on August 11th. This sale, made to cover tax obligations from vested equity awards, reduced her holdings by 1.76%. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong earnings, exceeding analyst estimates, and currently has a mixed analyst consensus rating of "Hold" with an average price target of $8.57.
Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding
Rocket Pharmaceuticals (RCKT) Chief Operating Officer Christopher James Stevens sold 36,658 shares of common stock at $3.499 per share on August 11, 2026. This sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Following the transaction, Stevens directly holds 505,784 shares, including RSUs.
RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares
Martin Wilson, an insider at ROCKET PHARMACEUTICALS, INC. (RCKT), has filed a Form 144 notice to sell up to 3,493 common shares. These shares originated from a restricted stock vesting event on August 11, 2026, as compensation. The proposed sale is set for August 13, 2026, through Fidelity Brokerage Services LLC, and the filing also discloses two prior sales by Wilson in May 2026.
Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals
Gaurav Shah, an insider at RCKT (Rocket Pharmaceuticals, Inc.), has filed to sell 2,837 shares of common stock through Fidelity Brokerage Services LLC, valued at $9,592.18. This planned sale on August 13, 2026, is related to restricted stock vesting designated as compensation. This follows previous sales in May 2026 totaling over 60,000 shares for a combined value of approximately $188,916.32.
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $10. This indicates a continued positive outlook on the company's stock performance by the firm.
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026)
This article reports on an SEC Form 144 filing by ROCKET PHARMACEUTICALS, INC. (RCKT) on August 11, 2026. The filing details the proposed sale of 36,658 shares of common stock acquired through restricted stock vesting on August 4, 2026, with an aggregate market value of $128,281.01. The sale is to be executed through Fidelity Brokerage Services LLC on NASDAQ.
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
Rocket Pharmaceuticals, Inc. is projected to report a loss of 42 cents per share. This information comes from an earnings preview, indicating upcoming financial results for the company.
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026)
ROCKET PHARMACEUTICALS, INC. filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of securities. The filing details the acquisition of 4701 shares of common stock through restricted stock vesting on August 5, 2026, and their intended sale via Fidelity Brokerage Services LLC on NASDAQ. This filing is deemed neutral in both impact and sentiment by AI analysis.
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals announced its Q2 2026 financial results, reporting $283.7 million in cash, cash equivalents, and investments, providing a cash runway into Q2 2028. Key milestones include FDA approval of KRESLADI™ and the sale of its Priority Review Voucher for $180 million, alongside positive safety findings for RP-A501 in Danon disease, with further regulatory and clinical updates expected in the second half of 2026 for its cardiovascular pipeline. The company also reported a net income of $123.2 million for the quarter, a significant improvement from a net loss in the prior year.
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley analyst Michael Ulz has reiterated a "Hold" rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $5. According to TipRanks data, Ulz has a 45.3% success rate and a 2.5% average return over the past year. This report emphasizes that the information is for informational purposes only and not investment advice.
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals announced its second-quarter 2026 financial results, highlighting the FDA approval of KRESLADI™ and the subsequent sale of its Priority Review Voucher for $180 million. The company also reported positive initial safety findings for RP-A501 in Danon disease and anticipates further clinical and regulatory milestones across its cardiovascular pipeline. Rocket projects a cash runway into the second quarter of 2028 based on its current financial position.
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals (RCKT) reported Q2 2026 earnings of $1.08 per share, significantly beating the Zacks Consensus Estimate, contrasting with a loss in the prior year. The company saw reduced general and administrative and R&D expenses. Key updates include the ongoing launch preparations for its FDA-approved gene therapy Kresladi, with patient onboarding expected in Q4 2026, and positive initial safety findings for its investigational gene therapy RP-A501 for Danon disease.
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside
Rocket Pharmaceuticals, Inc. (RCKT) has seen its average 12-month price target reduced to $8.84 from $9.39 by 11 analysts. Despite the cut, this new target still suggests a significant 143% potential upside based on the Aug. 10 closing price. The consensus rating among 15 analysts remains a "Buy," with a breakdown of 6 Buys, 7 Holds, and 2 Sells.
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15
Wedbush has maintained its 'Outperform' rating for Rocket Pharmaceuticals (RCKT) but lowered its price target from $16.00 to $15.00. The company's current stock price is $3.49, suggesting it is trading at a significant discount to the revised target. Despite some guru confidence, insider selling and a low GF Score of 32/100, particularly in profitability, indicate potential challenges and advise caution for investors.
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals (RCKT) reported Q2 2026 earnings of $1.08 per share, a significant increase from a loss in the prior year, surpassing the Zacks Consensus Estimate. The company also highlighted the ongoing launch preparations for its FDA-approved gene therapy, Kresladi, for severe LAD-I, and provided updates on other pipeline candidates for Danon disease and arrhythmogenic cardiomyopathy.
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Wedbush has lowered its price target for Rocket Pharmaceuticals (NASDAQ:RCKT) from $16 to $15, while maintaining an "outperform" rating, indicating a significant potential upside from its current price of $3.40. The stock recently fell by 6.7%, and analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $8.57. Despite recent insider selling, institutional investors and hedge funds largely hold or are building positions, owning approximately 98.4% of the stock.
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.93, Implies 145% Upside
Analysts have cut the 12-month price target for Rocket Pharmaceuticals, Inc. (RCKT) stock to $8.93, down from $9.39, but this still implies a 145% potential upside from its August 10th closing price. The consensus rating from 15 analysts remains "Buy," with a breakdown of 6 Buys, 7 Holds, and 2 Sells.
ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12
LEERINK PARTNERS has cut its target price for ROCKET PHARMACEUTICALS, INC. (RCKT.O) from $12 to $7. This information was reported by Reuters on August 11, 2026. The article advises readers that its content reflects only the author's opinion and should not be used as investment advice.
ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings
ROCKET PHARMACEUTICALS ($RCKT) reported its Q2 2026 earnings, missing both earnings per share and revenue estimates. The company posted an EPS of -$0.15 against an estimated $0.25, and zero revenue against an estimated $20.4 million. Insider trading data shows 12 sales and no purchases in the last 6 months, while institutional holdings saw significant additions and removals by various funds.
Rocket Pharmaceuticals Q2 Results: Net income turns positive on PRV sale
Rocket Pharmaceuticals reported a Q2 adjusted EPS of $(0.37), missing analyst estimates, but achieved a headline net income of $123.2 million due to a $178.2 million gain from a Rare Pediatric Disease Priority Review Voucher (PRV) sale. This non-recurring gain significantly boosted the company's cash reserves to $283.7 million, which is expected to fund operations into Q2 2028. The company also demonstrated improved operational efficiency, with total operating expenses decreasing, and provided updates on its cardiovascular gene therapy pipeline and the commercialization of KRESLADI.
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of $1.08, which significantly surpassed analyst estimates of $0.86 by $0.22. Following the announcement, the biotechnology company's shares rose by 0.8% to $3.64. Despite a mixed analyst sentiment with a "Hold" consensus and a target price of $8.71, institutional investors maintain a substantial 98.39% ownership of the stock, while the company demonstrates strong financial health with high liquidity ratios and low debt.
Rocket Pharmaceuticals, Inc. (RCKT) Class Action Lawsuit: Levi
Levi & Korsinsky reminds investors of the August 11, 2025 deadline to join a class action lawsuit against Rocket Pharmaceuticals, Inc. (RCKT). The lawsuit alleges that Rocket Pharmaceuticals made misleading statements and concealed material adverse facts regarding the safety and clinical trial protocol of its RP-A501 drug, specifically concerning serious adverse events including a patient's death. The company allegedly failed to disclose a critical protocol amendment to shareholders, leading to a significant stock price drop following the FDA's clinical hold announcement.
Rocket Pharmaceuticals, Inc. Revenue Breakdown – BOATS:RCKTW
This article provides a brief overview of Rocket Pharmaceuticals, Inc. (RCKTW) and its financial data, specifically focusing on its revenue breakdown. It indicates that the company's financial information, including segments and regional performance, is available through TradingView, which sources data from ICE Data Services and FactSet. The content primarily highlights the availability of financial statistics and market data for RCKTW.
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com
This article announces the filing of Form 4 for Rocket Pharmaceuticals Inc. on August 6, as reported by Investing.com. It is a brief notification indicating a regulatory filing by the company. The content primarily consists of navigation and market data, with minimal textual information about the filing itself.
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com
This article from Investing.com reports on a Form 4 filing for Rocket Pharmaceuticals Inc, specifically for August 6th. The content is very brief, serving primarily as an announcement of the filing and a link to view related information.
Rocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease
Rocket Pharmaceuticals announced positive clinical safety results from the first three patients in its modified Phase 2 trial of RP-A501 for Danon disease. The patients, treated with a recalibrated dose and refined immunomodulatory regimen, showed no significant safety concerns. The company is now engaging with the FDA to finalize the pathway for treating additional patients and aims to provide further updates in the second half of 2026.
Rocket Pharma reports early safety data for Danon disease therapy
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) announced early positive safety data for its gene therapy RP-A501 in the pivotal Phase 2 trial for Danon disease. The first three patients treated under a modified protocol showed no significant safety concerns. The company is collaborating with the FDA to proceed with the trial and expects to provide a regulatory pathway update in the second half of 2026.
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
Rocket Pharmaceuticals (RCKT) announced positive early safety data from the first three patients in its Phase 2 trial for Danon disease, a rare genetic heart condition. The trial utilized a modified protocol with a recalibrated dose of RP-A501 and a refined immunomodulatory regimen, showing no significant safety concerns. The company is in discussions with the FDA regarding the next steps for dosing the remaining trial participants.
Rocket Pharmaceuticals Inc expected to post earnings of 37 cents a share - Earnings Preview
Rocket Pharmaceuticals Inc (RCKT) is expected to announce its earnings, with analysts projecting a loss of 37 cents per share. This preview indicates the anticipated financial performance for the upcoming earnings report. The full article from Reuters is available on TradingView for those seeking more in-depth information.
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Rocket Pharmaceuticals has announced positive clinical safety results from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The patients received a recalibrated dose of RP-A501 with a refined immunomodulatory regimen and exhibited no thrombotic microangiopathy (TMA), capillary leak syndrome, or other significant safety concerns. The company is now actively engaging with the FDA to align on the path for treating additional patients and completing the pivotal trial, with a regulatory pathway update expected in the second half of 2026.
Vanguard Portfolio Management (RCKT) reports 5.35% Rocket Pharmaceuticals ownership
Vanguard Portfolio Management has disclosed a passive ownership stake of 5.35% in Rocket Pharmaceuticals Inc. common stock, totaling 5,847,541 shares as of June 30, 2026. Vanguard maintains sole voting power over 37,508 shares and sole dispositive power over all its beneficially owned shares, with no shared voting or dispositive power. This filing indicates that Vanguard and its affiliates act for investment purposes, not to influence control of the issuer.
Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Rocket Pharmaceuticals Inc (RCKT), indicating a weak financial status with a score of 5.45 out of 385 in its industry. It highlights low operating efficiency and mentions that relevant financial data for various categories like cash flow, revenue, and assets have not yet been disclosed by the company.
Rocket Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RCKTW
This page on TradingView.com provides an overview of Rocket Pharmaceuticals, Inc. (RCKTW) and focuses on its financial data, specifically the revenue breakdown. It lists various sections like financials, documents, news, and community, indicating that the detailed revenue breakdown would be accessible within the financial statements or segments section. The article itself does not provide specific revenue figures but guides users to where they can find such information on the platform.
Rocket Pharmaceuticals Inc (RC
This article provides a technical analysis of Rocket Pharmaceuticals Inc (RCKT), detailing its current price momentum score, support and resistance levels, and various technical indicators. It also presents an analysis of moving averages and offers FAQs regarding technical ratings, moving averages, and technical buy/sell signals for RCKT.
Rocket Pharmaceuticals Inc (RCKT) Institutional Confidence
Rocket Pharmaceuticals Inc (RCKT) has a high institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Institutional shareholding increased by 7.06% quarter-over-quarter, with the largest institutional holder being Bill Nygren | OAKMX, despite a decrease in their holdings. The report details the top institutional shareholders and their changes in shareholding.
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Rocket Pharmaceuticals Inc (RCKT), indicating that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder for financial analysis that will be updated once more information becomes available from Rocket Pharmaceuticals. The current stock price and market capitalization are presented.
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Rocket Pharmaceuticals Inc (RCKT) shareholder structure, including major shareholders and institutional holdings. It lists the top individual shareholders and their proportional stakes, categorizes shareholder types, and tracks changes in institutional shareholding over recent quarters. The report also identifies related ETFs that hold RCKT stock.
RCKT|Rocket Pharmaceuticals Inc|Price:3.190|Chg%:-0.090
This article provides a comprehensive financial summary of Rocket Pharmaceuticals Inc (RCKT), including its income statement, balance sheet, and cash flow statement. It details quarterly and annual financial indicators such as EPS, Revenue, Net Profit, Debt to Assets ratio, and outlines upcoming earnings information with a "HOLD" analyst rating. The data presented covers multiple fiscal years, highlighting performance trends for investors.
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT) - Join by August 11, 2025 - Contact Levi & Korsinsky
A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (RCKT) alleging securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims the company withheld critical information about Serious Adverse Events, including patient death, in its RP-A501 clinical trial, leading to artificially inflated stock prices. Following the FDA placing a clinical hold on the study and the disclosure of a patient's death, Rocket's stock dramatically declined, causing significant losses for investors.
